MiRXES has developed a novel quantitative Polymerase Chain Reaction (qPCR) assay platform technology that measures biofluid borne (Serum, plasma, urine etc) miRNAs with unparalleled sensitivity, specificity and robustness. MiRXES' platform technology is able to detect 590+ miRNAs in biofluids compared to our 3 major competitors, Qiagen, Exiqon and ABI, which are only able to detect less than 150.

The platform has enabled the MiRXES team to identify novel blood borne miRNA biomarkers with exceptional performance in detecting early stage breast, gastric and lung cancers. By combining our proprietary qPCR assays and novel biomarkers, MiRXES is developing blood miRNA based in-vitro diagnostic (IVD) tests to address critical clinical unmet needs in the screening of these cancers. To date MiRXES has performed the largest clinical studies for miRNA based diagnostic tests for early stage breast, gastric as well as lung cancer diagnosis in the world.

We started with cancer but our mid term goal is to identify novel miRNA biomarkers and develop non-invasive clinical diagnostic tests for early detection and personalized management of life-threatening and chronic diseases. Being a key class of genetic regulator, miRNAs are intimately involved in almost all biological processes and pathological conditions. As a result, a wide range of researchers from clinical institutions, biotech and pharmaceutical companies use MiRXES research products and services to identify clinically relevant miRNA biomarkers and therapeutic targets over a wide spectrum of disease domains. Biotech and pharmaceutical companies and their CROs are also incorporating such tests to identify and stratify patients during clinical trials. To this end MiRXES has started to branch out into metabolic, cardiovascular and infectious diseases among others.

In the long term, MiRXES aims to advance miRNA technologies and provide premier life science tools that empower the research community for miRNA R&D. Basic sciences research groups from universities and polytechnics use MiRXES' research assays to investigate the biology of miRNA in human and animal species. Agri-veterinary companies investigate the use of miRNA either as a marker to identify high producers or as a modifiable target to improve livestock and crop yields. Nutraceutical and cosmeceutical industries are starting to develop miRNA tools for product quality control and personalized treatment. In all cases, miRNA expression analysis using qPCR assays form an integral part of experimentation. MiRXES is starting to break into all these markets.